GlassScriptPhysician profile
Neil Anderson
NPI 1265675094
$41,398.42
in general payments reported to CMS, 2019-2025
8 companies · $19.19 in 2025
The $19.19 reported for 2025 was less than what a typical Clinical Pathology/Laboratory Medicine provider received nationally (typical 2025 total: $114).
See the full distribution for Clinical Pathology/Laboratory Medicine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $13K · 2021: $7,500 · 2022: $4,138 · 2023: $1,000 · 2024: $3,143 · 2025: $19.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,143 · Food and Beverage: $19.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,142.50 |
| Food and Beverage | $19.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Diasorin Molecular LLC | $26,898.73 | 2019-2022 | |
| Biofire Diagnostics, LLC | $5,200.00 | 2020 | |
| Roche Diagnostics Corporation | $3,142.50 | 2024 | |
| Quidel Corporation | $3,000.00 | 2021 | |
| Roche Molecular Systems, INC. | $2,100.00 | 2022 | |
| Luminex Corporation | $1,000.00 | 2023 | |
| Cepheid | $38.00 | 2022 | |
| Shionogi INC | $19.19 | 2025 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.